DOC

DOC (2,5-dimethoxy-4-chloroamphetamine) is a synthetic hallucinogenic amphetamine of the DOx structural class, characterized by potent and selective partial agonism at the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors and an extended duration of psychoactive effects (12 to 24 hours) that substantially exceeds that of classical indoleamine psychedelics such as psilocybin and N,N-dimethyltryptamine. The compound was first synthesized in 1973 by Coutts and Malicky at the University of Alberta as part of a systematic structure-activity investigation of 4-substituted analogs of DOM (2,5-dimethoxy-4-methylamphetamine). Alexander Shulgin subsequently characterized the compound through informal human bioassays and documented its synthesis, dosage, and phenomenology in PiHKAL: A Chemical Love Story (1991), establishing the psychoactive dose range at approximately 1.5 to 3.0 mg orally.

The molecular pharmacology of DOC is defined by high-affinity binding at the 5-HT2A receptor (Ki approximately 1.4 to 12 nM), with functional partial agonist activity (EC50 approximately 0.6 to 11 nM, Emax 58 to 102 percent of serotonin maximum depending on assay system) and substantially lower affinity at 5-HT1A (Ki greater than 5,000 nM), dopamine D2 (Ki greater than 1,000 nM), and monoamine transporter sites (IC50 greater than 10,000 nM for SERT, NET, and DAT). The compound is pharmacologically inert as a monoamine releasing agent and reuptake inhibitor, distinguishing it mechanistically from stimulant amphetamines and placing its activity squarely within the serotonergic psychedelic class. In rodent behavioral models, DOC produces the head-twitch response (a validated 5-HT2A-dependent behavioral proxy for psychedelic activity), fully substitutes for the discriminative stimulus of DOM and LSD in drug discrimination paradigms, and has demonstrated conditioned place preference and self-administration behavior in some experimental protocols.

Pharmacokinetics in humans are incompletely characterized but are consistent with good oral bioavailability, delayed onset (60 to 120 minutes), and a prolonged effect duration reflecting the stability of the 4-chloro substituent and the extended receptor residence time. Hepatic metabolism proceeds principally through CYP2D6-mediated O-demethylation of the 2- or 5-position methoxy groups, followed by oxidative deamination to form active metabolites. The CYP2D6 dependence introduces a pharmacogenomic variable that has not been systematically studied in human subjects but is predicted to produce inter-individual variability in exposure and effect duration analogous to that observed with other 2,5-dimethoxyamphetamine derivatives.

Clinical data on DOC are limited to case reports and forensic toxicology documentation. Published case series describe five non-fatal exposures presenting with tonic-clonic seizures, agitation, hyperthermia, visual hallucinations, and aggression, with plasma concentrations below 18 micrograms per liter. At least two fatalities have been attributed to DOC, including one case in which DOC was identified as the sole causative agent at autopsy, with findings of pulmonary edema and subgaleal hemorrhage. Blood or plasma concentrations in the range of 1 to 10 micrograms per liter are expected during recreational use, with concentrations exceeding 20 micrograms per liter associated with clinical intoxication and concentrations above 100 micrograms per liter observed in acute overdose.

DOC was internationally controlled under United Nations Psychotropic Schedule I following a 2019 recommendation by the Expert Committee on Drug Dependence. In the United States, the Drug Enforcement Administration placed DOC (and DOI) in Schedule I of the Controlled Substances Act in 2022. The compound is classified as a controlled substance in Canada, the United Kingdom, Germany, Sweden, Denmark, China, Brazil, and other jurisdictions. Research-grade material is available as an analytical reference standard from certified suppliers (Cayman Chemical, Cerilliant, others) under appropriate licensing; investigators must comply with all applicable controlled substance regulations in their jurisdiction. This monograph reviews the chemistry, synthesis, and stereochemistry of DOC; the receptor pharmacology and 5-HT2A signaling cascade; the pharmacokinetic and metabolic profile; the preclinical behavioral pharmacology; the clinical case evidence and forensic toxicology; sourcing and handling considerations; stack interactions; adverse events and safety signal; and a comparative assessment of five structurally related DOx and phenethylamine psychedelic compounds (DOI, DOB, DOM, mescaline, 2C-B) against DOC on five competency standards.